Shamburg News · 8-K filed Oct 22, 2026, 5:28 PM EDT

PAVmed Subsidiary Lucid Diagnostics Closes $15.0 Million Series C Preferred Stock Offering

PAVM · PAVmed Inc.

  • Financing
  • Material agreement
  • Materiality: medium

Effective October 21, 2026, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., entered into subscription agreements with accredited investors for 15,000 shares of newly designated Series C Convertible Preferred Stock at $1,000 per share. The closing occurred the same day with gross proceeds of $15.0 million. Lucid Diagnostics also filed a Certificate of Designations with Delaware and entered into a registration rights agreement covering resale of underlying common stock.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 3.03, 5.03, 9.01, accession 0001493152-26-048138.

Written from the filing by Shamburg Markets. Figures are as reported by the company.